Neurogene Inc. NGNE R2K
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -21.2% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NGNE Neurogene Inc. R2K | 28.34 | - | $447.83M | - | -33.19% | -37.25% | - | -21.24% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 25.92M | 26.08M | 23.80M | 27.53M | 33.35M |
| Operating Income | - | -25.92M | -26.08M | -23.80M | -27.53M | -33.35M |
| EBITDA | - | -21.88M | -21.25M | -20.18M | -23.95M | -30.08M |
| Interest Expense | - | 2.00K | 1.00K | 1.00K | 1.00K | 0 |
| Pretax Income | - | -22.65M | -22.02M | -20.95M | -24.73M | -30.93M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | - | -22.65M | -22.02M | -20.95M | -24.73M | -30.93M |
| Diluted EPS | -1.19 | -1.08 | -1.05 | -0.99 | - | -1.39 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 925.00K | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 56.52M | 55.58M | 83.53M | 103.33M |
| Operating Income | - | -56.52M | -55.58M | -82.61M | -103.33M |
| EBITDA | - | -51.99M | -33.01M | -71.89M | -87.25M |
| Interest Expense | - | 2.00K | 12.00K | 12.00K | 5.00K |
| Pretax Income | - | -55.19M | -36.32M | -75.14M | -90.35M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -55.19M | -36.32M | -75.14M | -90.35M |
| Diluted EPS | -34.60 | -37.80 | -73.83 | -4.28 | - |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -21.24% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +66.61% |
| 6 Months: | +36.64% |
| 3 Months: | +20.65% |
| 1 Month: | +7.02% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 109.27M | 222.57M | 335.73M | 288.60M |
| Current Assets | - | 84.72M | 200.35M | 315.92M | 271.77M |
| Cash & Equivalents | - | 82.02M | 148.21M | 136.59M | 103.84M |
| Inventory | - | - | - | - | - |
| Receivables | - | 990.00K | 600.00K | 648.00K | 460.00K |
| Total Liabilities | - | 255.00M | 36.55M | 25.36M | 23.72M |
| Current Liabilities | - | 6.65M | 22.97M | 15.16M | 16.41M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 4.69M | 16.25M | 14.24M | 10.96M |
| Total Equity | - | -145.74M | 186.02M | 310.38M | 264.89M |
| Shares Outstanding | - | 12.82M | 12.82M | 14.85M | 15.49M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -52.82M | -51.42M | -70.60M | -77.17M |
| Investing Cash Flow | - | -2.23M | 25.64M | -125.26M | 14.00M |
| Financing Cash Flow | - | 66.53M | 92.48M | 184.07M | 30.43M |
| Capital Expenditure | - | -2.23M | -321.00K | -808.00K | -1.18M |
| Free Cash Flow | - | -55.05M | -51.74M | -71.41M | -78.36M |
| Net Change in Cash | - | 11.48M | 66.70M | -11.79M | -32.74M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | -8,930.3% | - |
| Net Margin % | - | - | - | -8,123.7% | - |
| ROE % | - | 37.9% | -19.5% | -24.2% | -34.1% |
| ROCE % | - | -55.1% | -27.8% | -25.8% | -38.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Samsara BioCapital, LLC | 10.87% | 1.72M | $48.66M |
| 2 | Redmile Group, LLC | 9.24% | 1.46M | $41.37M |
| 3 | Casdin Capital, LLC | 8.99% | 1.42M | $40.25M |
| 4 | RTW Investments LP | 8.62% | 1.36M | $38.61M |
| 5 | EcoR1 Capital, LLC | 8.05% | 1.27M | $36.03M |
| 6 | Blackrock Inc. | 6.36% | 1.01M | $28.48M |
| 7 | Baker Bros. Advisors, LP | 6.28% | 991.69K | $28.10M |
| 8 | Trails Edge Capital Partners, LP | 4.95% | 782.79K | $22.18M |
| 9 | Balyasny Asset Management LP | 4.55% | 718.39K | $20.36M |
| 10 | Toronto Dominion Bank | 4.31% | 681.34K | $19.31M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NGNE